165 related articles for article (PubMed ID: 32218835)
1. Gene expression profiling identified TP53
Cheng J; Ding X; Xu S; Zhu B; Jia Q
Oncol Lett; 2020 Apr; 19(4):2817-2824. PubMed ID: 32218835
[TBL] [Abstract][Full Text] [Related]
2. Predictive Biomarker Profiling of > 6000 Breast Cancer Patients Shows Heterogeneity in TNBC, With Treatment Implications.
Millis SZ; Gatalica Z; Winkler J; Vranic S; Kimbrough J; Reddy S; O'Shaughnessy JA
Clin Breast Cancer; 2015 Dec; 15(6):473-481.e3. PubMed ID: 26051240
[TBL] [Abstract][Full Text] [Related]
3. Multi-Omics Profiling Reveals Distinct Microenvironment Characterization and Suggests Immune Escape Mechanisms of Triple-Negative Breast Cancer.
Xiao Y; Ma D; Zhao S; Suo C; Shi J; Xue MZ; Ruan M; Wang H; Zhao J; Li Q; Wang P; Shi L; Yang WT; Huang W; Hu X; Yu KD; Huang S; Bertucci F; Jiang YZ; Shao ZM;
Clin Cancer Res; 2019 Aug; 25(16):5002-5014. PubMed ID: 30837276
[TBL] [Abstract][Full Text] [Related]
4. Combination of Immune-Related Network and Molecular Typing Analysis Defines a Three-Gene Signature for Predicting Prognosis of Triple-Negative Breast Cancer.
Zhang J; Pan S; Han C; Jin H; Sun Q; Du J; Han X
Biomolecules; 2022 Oct; 12(11):. PubMed ID: 36358906
[TBL] [Abstract][Full Text] [Related]
5. Identification of Breast Cancer Immune Subtypes by Analyzing Bulk Tumor and Single Cell Transcriptomes.
Yao J; Li S; Wang X
Front Cell Dev Biol; 2021; 9():781848. PubMed ID: 35047498
[No Abstract] [Full Text] [Related]
6. Classification of triple-negative breast cancers based on Immunogenomic profiling.
He Y; Jiang Z; Chen C; Wang X
J Exp Clin Cancer Res; 2018 Dec; 37(1):327. PubMed ID: 30594216
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoints expression patterns in early-stage triple-negative breast cancer predict prognosis and remodel the tumor immune microenvironment.
Zhang J; Jin H; Pan S; Han C; Sun Q; Han X
Front Immunol; 2023; 14():1073550. PubMed ID: 36814908
[TBL] [Abstract][Full Text] [Related]
8. Genetic alterations of triple negative breast cancer (TNBC) in women from Northeastern Mexico.
Uscanga-Perales GI; Santuario-Facio SK; Sanchez-Dominguez CN; Cardona-Huerta S; Muñoz-Maldonado GE; Ruiz-Flores P; Barcenas-Walls JR; Osuna-Rosales LE; Rojas-Martinez A; Gonzalez-Guerrero JF; Valero-Gomez J; Gomez-Macias GS; Barbosa-Quintana A; Barboza-Quintana O; Garza-Guajardo R; Ortiz-Lopez R
Oncol Lett; 2019 Mar; 17(3):3581-3588. PubMed ID: 30867801
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy for Triple-Negative Breast Cancer: Combination Strategies to Improve Outcome.
Li L; Zhang F; Liu Z; Fan Z
Cancers (Basel); 2023 Jan; 15(1):. PubMed ID: 36612317
[TBL] [Abstract][Full Text] [Related]
10. The Evolution of Triple-Negative Breast Cancer: From Biology to Novel Therapeutics.
Anders CK; Abramson V; Tan T; Dent R
Am Soc Clin Oncol Educ Book; 2016; 35():34-42. PubMed ID: 27249684
[TBL] [Abstract][Full Text] [Related]
11. HDAC inhibition potentiates immunotherapy in triple negative breast cancer.
Terranova-Barberio M; Thomas S; Ali N; Pawlowska N; Park J; Krings G; Rosenblum MD; Budillon A; Munster PN
Oncotarget; 2017 Dec; 8(69):114156-114172. PubMed ID: 29371976
[TBL] [Abstract][Full Text] [Related]
12. Distinct Somatic Alteration Features Identified by Gene Panel Sequencing in Korean Triple-Negative Breast Cancer with High Ki67 Expression.
Sun WY; Lee J; Kim BK; Kim JO; Park J
Diagnostics (Basel); 2021 Mar; 11(3):. PubMed ID: 33804295
[TBL] [Abstract][Full Text] [Related]
13. Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer.
Telli ML; Stover DG; Loi S; Aparicio S; Carey LA; Domchek SM; Newman L; Sledge GW; Winer EP
Breast Cancer Res Treat; 2018 Aug; 171(1):21-31. PubMed ID: 29736741
[TBL] [Abstract][Full Text] [Related]
14. Triple-negative breast cancer: advancements in characterization and treatment approach.
Hurvitz S; Mead M
Curr Opin Obstet Gynecol; 2016 Feb; 28(1):59-69. PubMed ID: 26694831
[TBL] [Abstract][Full Text] [Related]
15. Cytotoxic T-lymphocyte infiltration and chemokine predict long-term patient survival independently of tumor mutational burden in triple-negative breast cancer.
Katsuta E; Yan L; Opyrchal M; Kalinski P; Takabe K
Ther Adv Med Oncol; 2021; 13():17588359211006680. PubMed ID: 33868461
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
[TBL] [Abstract][Full Text] [Related]
17. Tumor mutation burden, immune checkpoint crosstalk and radiosensitivity in single-cell RNA sequencing data of breast cancer.
Jang BS; Han W; Kim IA
Radiother Oncol; 2020 Jan; 142():202-209. PubMed ID: 31767471
[TBL] [Abstract][Full Text] [Related]
18. Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer.
Ricciuti B; Kravets S; Dahlberg SE; Umeton R; Albayrak A; Subegdjo SJ; Johnson BE; Nishino M; Sholl LM; Awad MM
J Immunother Cancer; 2019 Mar; 7(1):87. PubMed ID: 30922388
[TBL] [Abstract][Full Text] [Related]
19. KRAS signaling enriched triple negative breast cancer is associated with favorable tumor immune microenvironment and better survival.
Tokumaru Y; Oshi M; Katsuta E; Yan L; Satyananda V; Matsuhashi N; Futamura M; Akao Y; Yoshida K; Takabe K
Am J Cancer Res; 2020; 10(3):897-907. PubMed ID: 32266098
[TBL] [Abstract][Full Text] [Related]
20. Analysis of PIK3CA Mutations and Activation Pathways in Triple Negative Breast Cancer.
Cossu-Rocca P; Orrù S; Muroni MR; Sanges F; Sotgiu G; Ena S; Pira G; Murgia L; Manca A; Uras MG; Sarobba MG; Urru S; De Miglio MR
PLoS One; 2015; 10(11):e0141763. PubMed ID: 26540293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
